RxDoctor Payments Data

Lance Turkish, MD

Ophthalmology · New Orleans, LANPI 1881626497

Payments from drug & device makers

$1,405in general payments, 2019–2025

Across 56 payments — averaging $25.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$348
  • Aerie Pharmaceuticals, Inc.$317
  • Apellis Pharmaceuticals, Inc.$152
  • Sun Pharmaceutical Industries Inc.$121
  • Omeros Corporation$79
  • Mallinckrodt Hospital Products Inc.$66
  • plus $320 from 11 others

What the payments were for

  • Food & beverage$1,36097%
  • Gifts$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,405 in reported general payments places this provider in the 40th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$228,388
Medicare patients
299
Services billed
3,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Alphagan PBrimonidine Tartrate108$44,486
RhopressaNetarsudil Mesylate25$15,828
VyzultaLatanoprostene Bunod37$15,614
LumiganBimatoprost34$15,405
RestasisCyclosporine13$12,091
RocklatanNetarsudil Mesylat/Latanoprost18$9,896
SimbrinzaBrinzolamide/Brimonidine Tart26$7,644
Brinzolamide27$7,200
CombiganBrimonidine Tartrate/Timolol14$6,463
Brimonidine Tartrate16$4,881
ProlensaBromfenac Sodium11$4,081
Timolol Maleate32$2,949
Bromfenac Sodium16$2,209
Dorzolamide-TimololDorzolamide/Timolol/Pf17$1,109
Dorzolamide Hcl49$539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieAlphagan P, Lumigan, Restasis, Combigan$348$78,445169 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$317$25,72343 claims
Bausch & Lomb Americas Inc.Vyzulta$36$15,61437 claims
AlconSimbrinza$31$7,64426 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$59$4,08111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →